The National Cancer Institute (NCI) awarded a $458,698 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Regents of the University of Michigan to conduct research on identifying novel gene drivers that contribute to therapy resistance and relapse in acute myeloid leukemia (AML). The project aims to functionally validate a candidate pool of genes identified through single-cell RNA sequencing and CRISPR screens in primary human AML samples, with the goal of improving understanding of the complex mechanisms underlying AML relapse. The research will be conducted by the University of Michigan over a 5-year period from March 2025 through February 2030. This grant supports the NCI's Cancer Biology Research program, which funds fundamental investigations into the cellular and molecular underpinnings of cancer development, progression, and potential interventions.
Generated 3/25/25, 5:19 AM